Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up (Q34142287)

31 July 2017

1 reference

title

Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up (English)

1 reference

31 July 2017

1 reference

1 reference

Carroll P

1

1 reference

31 July 2017

Coley C

2

1 reference

31 July 2017

McLeod D

3

1 reference

31 July 2017

Schellhammer P

4

1 reference

31 July 2017

Sweat G

5

1 reference

31 July 2017

Wasson J

6

1 reference

31 July 2017

Zietman A

7

1 reference

31 July 2017

Thompson I

8

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

57

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

225-229

1 reference

Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Lymph node size does not correlate with the presence of prostate cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

The PSA nadir that indicates potential cure after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Cryosurgical ablation of prostate cancer: patterns of cancer recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900994-8

7 January 2021

10.1016/S0090-4295(00)00994-8

Identifiers

DOI

1 reference

31 July 2017

1 reference